Expression, Purification, Biochemical Characterization, and Comparative Function of Human Cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 Allelic Isoforms
Authors:
- Aiming YuAYAiming Yu
- Byron M. KnellerBKByron M. Kneller
- Allan E. RettieARAllan E. Rettie
- 1 January 2002
- journal article
- research article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 303 (3) , 1291-1300
Abstract
Polymorphism at the cytochrome P450 2D6 (CYP2D6) locus is one of the most widely known causes of pharmacogenetic variability in humans. Our goal is to investigate the intrinsic enzymatic differences that exist among active CYP2D6 isoforms to test the hypothesis that these enzymatic differences are substrate-dependent. Active CYP2D6.1, 2, 10, and 17 holo-enzymes were expressed in vitro and purified to a high degree of homogeneity as confirmed with SDS-polyacrylamide gel electrophoresis, CO-difference spectroscopy, and mass spectral analysis. Purified enzyme was reconstituted with lipid and cytochrome P450 reductase in a 2:1 ratio before kinetic analysis. The reaction rate for dextromethorphan (DXM)O-demethylation, DXM N-demethylation, codeine O-demethylation, and fluoxetineN-demethylation catalyzed by each of the variants was determined. The CYP2D6.10 enzyme was the most impaired, exhibiting an estimated enzyme efficiency (asVmax/Km) 50-fold lower for DXM O-demethylation and 100-fold lower for fluoxetine N-demethylation when compared with CYP2D6.1, whereas no measurable catalytic activity was observed for this variant toward codeine. The atypical DXM N-demethylation pathway catalyzed by this variant decreased only 2-fold in comparison. In the case of CYPD6.17, estimated clearances for each metabolite were decreased 6 to 33%. Likewise, the intrinsic clearance of CYP2D6.2 enzyme was consistently decreased for each reaction examined, indicating that the ultra-rapid metabolizer phenotype sometimes associated with this genotype is not a function of the underlying amino acid substitutions. Overall enzyme efficiencies for the metabolism of each substrate therefore decreased in the order of 2D6.1 > 2D6.2 > 2D6.17 > 2D6.10.Keywords
This publication has 37 references indexed in Scilit:
- The Decreased in Vivo Clearance of CYP2D6 Substrates by CYP2D6*10 Might Be Caused Not Only by the Low-Expression but Also by Low Affinity of CYP2D6Archives of Biochemistry and Biophysics, 2000
- Pharmacogenomics: Translating Functional Genomics into Rational TherapeuticsScience, 1999
- Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and CaucasiansPharmacogenetics, 1998
- Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 m RNA in human foetal and adult brain by in situ hybridizationXenobiotica, 1997
- Allelic Variants of Human Cytochrome P450 2C9: Baculovirus-Mediated Expression, Purification, Structural Characterization, Substrate Stereoselectivity, and Prochiral Selectivity of the Wild-Type and I359L Mutant FormsArchives of Biochemistry and Biophysics, 1996
- Molecular basis of polymorphic drug metabolismJournal of Molecular Medicine, 1995
- Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine, and its metabolitesBiochemical Pharmacology, 1995
- Evolution of the P450 gene superfamily:Trends in Genetics, 1990
- Characterization of the common genetic defect in humans deficient in debrisoquine metabolismNature, 1988
- MPTP, the neurotoxin inducing parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylationBiochemical and Biophysical Research Communications, 1987